Cursos

← vista completa

Publicado el 1 de marzo de 2003 | http://doi.org/10.5867/medwave.2003.02.3181

Radiobiología y cinética celular aplicada al fraccionamiento del cáncer de próstata (parte 1)

Radiobiology and cell kinetics applied to the fractionation of prostate cancer (part 1)

Max Schorwer

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Max Schorwer

Clínica Sanatorio Alemán, Concepción, Chile

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Schorwer M. Radiobiology and cell kinetics applied to the fractionation of prostate cancer (part 1). Medwave 2003;3(02):e3181 doi: 10.5867/medwave.2003.02.3181

Publicación 01/03/2003

Métricas del artículo

Artículo no tiene métricas.

Notas

Referencias

  1. Hall EJ. Radiobiology for the Radiologist. Fourth edition. Philadelphia, J.B.Lippincott Company,1994, p. 219-21.
  2. Gunderson LL, Tepper JE. Clinical Radiation Oncology. Philadelphia, Churchill Livingstone, Harcourt Health Sciences, 2000.
  3. Perez CA, Brady LW. Priciples and practices of Radiation Oncology. Lippincott Williams & Wilkins,1997. De Vita VT. Cáncer Principios y Práctica de Oncología. Panamericana, 2000.
  4. De Vita VT. Cáncer Principios y Práctica de Oncología. Panamericana, 2000.
  5. Thames. An incomplete repair model for survival after fractionated and continuous irradiations.IJROBP 1985;47:319-339.
  6. Fowler JF, Ritter MA. A rationale for fractionation for slowly proliferating tumors such as prostatics adenocarcionoma. Int J Radiat Oncol Biol Phys. 1995 May 15;32(2):521-9. | CrossRef
  7. Pollack A, Zagars GK, Kavadi VS. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer. 1994 Jul 15;74(2):670-8. | CrossRef
  8. Kabalin JN, McNeal JE, Johnstone IM, Stamey TA. Serum prostate specific antigen and the biologic progression of prostate cancer. Urology. 1995 Jul;46(1):65-70. | CrossRef
  9. Haustermans KM, Hofland I, Van Poppel H, Oyen R, Van de Voorde W, Begg AC, et al. Cell kinetics measurements in prostate cancer. Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1067-70. | CrossRef
  10. Scrivner DL, Meyer JS, Rujanavech N, Fathman A, Scully T. Cell kinetics by bromodeoxyyuridine labeling and deoxiribonuleic acid ploidy in prostatic carcinoma needle biopsies. J Urol. 1991 Oct;146(4):1034-9. | PubMed
  11. Mohan DS, Kupelian PA, Willoughby TR. Short –course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland. Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):575-80. | CrossRef
  12. Thames HD Jr, Withers HR, Peters LJ, Fletcher GH. Changes in early and late radiation responses with altered dose fractionation: Implications for dose-survival relationships. Int J Radiat Oncol Biol Phys. 1982 Feb;8(2):219-26. | CrossRef
  13. Duchesne GM, Peters LJ. What is the alpha beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):747-8. | PubMed
  14. Brenner DJ, Hall EJ. Fractionation and protaction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1095-101. | CrossRef
  15. Brenner DJ, Hall EJ. Low alpha beta values for prostate appear to be independent of modeling details. Int J Radiat Oncol Biol Phys. 2000 May1;47(2):538-539. | CrossRef
  16. Lloyd-Davies RW, Collins CD, Swan AV. Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years experience (1962-1984). Urology. 1990 Aug;36(2):107-11. | CrossRef
  17. Brenner. Toward optimal external-beam fractionation for prostate cancer. Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):315-6. | CrossRef
  18. Read G, Pointon RC. Retrospective study of radiotherapy in early carcinoma of the prostate. Br J Urol. 1989 Feb;63(2):191-5. | CrossRef | PubMed
  19. Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Schultheiss TE. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am. 1999 May-Jun;5(3):152-8. | PubMed
  20. Kupelian. Improvement in overall survival for patients with localized prostate cancer with higher than standard radiation doses: preliminary results. J Urology 1999 Feb2;161(2):386. | CrossRef
  21. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, et al. Dose escalation with tree-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):491-500. | CrossRef
  22. Zelefsky MJ, Fuks Z, Wolfe T, Kutcher GJ, Burman C, Ling CC, Venkatraman ES, Locally advanced prostatic cancer: long-term toxicity outcome after Three-dimensional conformal radiation therapy-a dose escalation study. Radiology. 1998 Oct;209(1):169-74. | PubMed
  23. Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, et al. Dose escalation with 3D conformal treatment: Five years outcomes, treatment optimizations, and future directions. Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):501-10. | CrossRef
  24. Pollack A, Zagars GK. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):1011-8. | CrossRef
  25. Collins CD, Lloyd-Davies RW, Swan AV. Radical external beam radiotherapy for localized carcinoma of the prostate using a hypofractionation technique. Clin Oncol (R Coll Radiol). 1991 May;3(3):127-32. | CrossRef
  26. Hanks GE, Schultheiss TE, Hanlon AL, Hunt M, Lee WR, Epstein BE, Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):543-50. | CrossRef
  27. Logue JP, Cowan RA, Hendry JH. Hypofractionation for prostate cancer. Int J Radiat Oncol Biol Phys. 2001 Apr 1;49(5):1522-3. | CrossRef